| Literature DB >> 31380089 |
Charles L Roesel1, Steven V Vollmer1.
Abstract
Anthozoans are a class of Cnidarians that includes scleractinian corals, anemones, and their relatives. Despite a global rise in disease epizootics impacting scleractinian corals, little is known about the immune response of this key group of invertebrates. To better characterize the anthozoan immune response, we used the model anemone Exaiptasia pallida to explore the genetic links between the anthozoan-algal symbioses and immunity in a two-factor RNA-Seq experiment using both symbiotic and aposymbiotic (menthol-bleached) Exaiptasia pallida exposed to the bacterial pathogen Vibrio coralliilyticus. Multivariate and univariate analyses of Exaiptasia gene expression demonstrated that exposure to live Vibrio coralliilyticus had strong and significant impacts on transcriptome-wide gene expression for both symbiotic and aposymbiotic anemones, but we did not observe strong interactions between symbiotic state and Vibrio exposure. There were 4,164 significantly differentially expressed (DE) genes for Vibrio exposure, 1,114 DE genes for aposymbiosis, and 472 DE genes for the additive combinations of Vibrio and aposymbiosis. KEGG enrichment analyses identified 11 pathways-involved in immunity (5), transport and catabolism (4), and cell growth and death (2)-that were enriched due to both Vibrio and/or aposymbiosis. Immune pathways showing strongest differential expression included complement, coagulation, nucleotide-binding, and oligomerization domain (NOD), and Toll for Vibrio exposure and coagulation and apoptosis for aposymbiosis.Entities:
Keywords: Cnidarian; Exaiptasia; aposymbiotic; gene expression; immune; symbiotic; transcriptome
Year: 2019 PMID: 31380089 PMCID: PMC6662555 DOI: 10.1002/ece3.5403
Source DB: PubMed Journal: Ecol Evol ISSN: 2045-7758 Impact factor: 2.912
Figure 1Outline of experimental design ‐ Thirty‐six anemones were divided into aposymbiotic and symbiotic. The aposymbiotic and symbiotic groups were then further subdivided with six symbiotic and six aposymbiotic anemones being sacrificed to estimate Symbiodinium densities due to menthol exposure leaving six symbiotic and six aposymbiotic anemones for Vibrio treatment and six symbiotic and six aposymbiotic controls
Multivariate PERMANOVAs show significant differences in transcriptome‐wide gene expression patterns due to Vibrio exposure (p = 0.001) and aposymbiosis (p = 0.007), but not the Vibrio‐aposymbiosis interaction
|
| SumsOfSqs | MeanSqs |
|
|
| |
|---|---|---|---|---|---|---|
| Vibrio | 1 | 0.045 | 0.045 | 6.065 | 0.199 | 0.001 |
| Apos. | 1 | 0.022 | 0.022 | 2.999 | 0.098 | 0.007 |
| Vibrio: Apos. | 1 | 0.011 | 0.011 | 1.432 | 0.047 | 0.136 |
| Residuals | 20 | 0.147 | 0.007 | 0.656 | ||
| Total | 23 | 0.224 | 1.000 |
Vibrio exposure explained 19.9% of the variation and menthol explained 9.8% of the variation.
Figure 2Multidimensional scaling (MDS) plot of mRNA shows differences among treatments with Vibrio exposure separated primarily on axis 1 and aposymbiosis separated along axis 2
Figure 3Plot of differentially expressed genes shows 2,155 genes up‐regulated and 1,552 down‐regulated for Vibrio, 353 genes down‐regulated and 322 up‐regulated for aposymbiosis, 230 genes up‐regulated for both Vibrio and aposymbiosis (V+A+), 142 genes down‐regulated for both Vibrio and aposymbiosis (V−A−), and 30 genes up‐regulated for Vibrio, but down‐regulated for aposymbiosis. Remaining groupings consisted of 21 or fewer genes. Red‐shaded areas show differentially expressed genes with KEGG ortholog annotations. Plot generated using the R package UpSetR (Conway, Lex, & Gehlenborg, 2017)
Differential gene expression summary of enriched (ESGEA) and overrepresented (GOseq) pathways, counts of DE genes (DESeq2) and total annotated genes within each pathway, and DE gene counts by direction and treatment group (DE for Vibrio‐only up [V+] or down [V−], aposymbiosis‐only up [A+] or down [A−], Both [V+A+, V−A−, V+A−])
| Pathway | Enriched | Overrepresented | Differential expression | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Pathway | V | A | V | A | DE/Total | V+ | V− | A+ | A− | V+A+ | V−A− | V+A− |
| Immune system | |||||||||||||
| ko04610 | Complement and coagulation cascades | *** | * | 0.004 | 0.153 | 11/14 | 6 | 0 | 0 | 0 | 4 | 1 | 0 |
| ko04062 | Chemokine signaling | *** | * | 16/35 | 10 | 4 | 0 | 1 | 0 | 1 | 0 | ||
| ko04612 | Antigen processing and presentation | 6/11 | 3 | 1 | 0 | 1 | 0 | 1 | 0 | ||||
| ko04670 | Leukocyte transendothelial migration | *** | 12/24 | 6 | 3 | 0 | 2 | 0 | 1 | 0 | |||
| ko04621 | NOD‐like receptor signaling | *** | 15/43 | 9 | 3 | 0 | 2 | 1 | 0 | 0 | |||
| Transport and catabolism | |||||||||||||
| ko04144 | Endocytosis | *** | * | 26/89 | 9 | 9 | 1 | 3 | 1 | 2 | 1 | ||
| ko04142 | Lysosome | *** | * | 12/62 | 7 | 0 | 2 | 2 | 0 | 1 | 0 | ||
| ko04146 | Peroxisome | *** | * | 20/48 | 0 | 13 | 3 | 1 | 1 | 2 | 0 | ||
| ko04145 | Phagosome | *** | 13/40 | 8 | 2 | 1 | 2 | 0 | 0 | 0 | |||
| Cell growth and death | |||||||||||||
| ko04210 | Apoptosis | ** | * | 14/38 | 7 | 4 | 1 | 2 | 0 | 0 | 0 | ||
| ko04115 | p53 signaling | *** | * | 5/24 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | ||
Counts for V−A+ were all zero, so the V−A+ column was excluded. Enrichment FDR‐adjusted p‐values: *0.05, **0.01, ***0.005.
Highly DE Immune genes by KEGG category and pathway
| Gene | Symbol | Pathway | Group |
| Apos. |
|---|---|---|---|---|---|
| Complement and coagulation cascades | |||||
| K03909 | TFPI1 | Tissue factor pathway inhibitor (coagulation) | V+A+ | 2.03 | 1.94 |
| K03900 | VWF | von Willebrand factor (coagulation) | V+A+ | 1.42 | 1.44 |
| K03906 | F13B | Coagulation factor XIII B polypeptide (coagulation) | V+ | 2.13 | 0.59 |
| K03910 | A2MG | Alpha‐2‐macroglobulin (coagulation) | V+ | 1.86 | 0.93 |
| K04007 | MCP | Membrane cofactor protein (complement) | V+ | 6.64 | 0.74 |
| K04006 | DAF | Decay‐accelerating factor (complement) | V+ | 2.96 | 1.17 |
| K01335 | CFAB | Component factor B [EC:3.4.21.47] (complement) | V+ | 1.78 | 0.46 |
| K03990 | CO3 | Complement component 3 (complement) | V+ | 1.59 | 0.62 |
| K04004 | CFAH | Complement factor H (complement) | V+ | 1.42 | 0.87 |
| K19821 | PAI2 | Plasminogen activator inhibitor 2 (complement) | V−A− | −1.31 | −1.05 |
| NOD‐like receptor signaling | |||||
| K04570 | B2CL1 | Bcl‐2‐like 1 (apoptosis regulator Bcl‐X) | V+ | 1.96 | 0.55 |
| K03174 | TRAF3 | TNF receptor‐associated factor 3 | V+ | 1.79 | 0.22 |
| K04729 | MY88A | Myeloid differentiation primary response protein MyD88 | V+ | 1.04 | −0.17 |
| K03173 | TRAF2 | TNF receptor‐associated factor 2 [EC:2.3.2.27] | V− | −1.02 | −0.42 |
| K08846 | RIPK2 | receptor‐interacting serine/threonine protein kinase 2 [EC:2.7.11.1] | V− | −1.36 | −0.63 |
| K04612 | CASR | Calcium‐sensing receptor | V− | −1.95 | −0.68 |
| Chemokine signaling | |||||
| K11224 | STAT1 | Signal transducer and activator of transcription 5B | V+ | 2.03 | 0.31 |
| K04189 | CXCR4 | C‐X‐C chemokine receptor type 4 | V− | −1.01 | −0.15 |
| K04538 | GBB4 | Guanine nucleotide‐binding protein subunit beta‐4 | V− | −1.02 | −0.5 |
| Antigen processing and presentation | |||||
| K06697 | PSME2 | Proteasome activator subunit 2 (PA28 beta) | V+ | 1.09 | −0.59 |
| K08062 | RFXK | Regulatory factor X‐associated ankyrin‐containing protein | A− | −0.95 | −1.22 |
Within pathways genes are grouped into up‐regulated for Vibrio and aposymbiosis (V+A+), up‐regulated for Vibrio‐only (V+), down‐regulated Vibrio and aposymbiosis (V−A−), down‐regulated for Vibrio‐only (V−), down‐regulated aposymbiosis‐only (A−). The Vibrio and Apos. columns show log fold change.
Highly DE transport and catabolism genes
| Gene | Symbol | Pathway | Group |
| Apos. |
|---|---|---|---|---|---|
| Endocytosis | |||||
| K12182 | HRS | hepatocyte growth factor‐regulated tyrosine kinase substrate | V+ | 1.69 | 0.15 |
| K04705 | HSE1 | signal transducing adaptor molecule | V+ | 1.07 | 0.19 |
| K04646 | CLH | clathrin heavy chain | V+ | 1.04 | 0.4 |
| K04189 | CXCR4 | C‐X‐C chemokine receptor type 4 | V− | −1.01 | −0.15 |
| K12196 | VPS4 | vacuolar protein‐sorting‐associated protein 4 | V− | −1.02 | −0.22 |
| K01115 | PLD2 | phospholipase D1/2 [EC:3.1.4.4] | V− | −1.31 | −0.65 |
| K13649 | JUNO | folate receptor | A− | −0.3 | −1.30 |
| Peroxisome | |||||
| K00308 | PAOX | N1‐acetylpolyamine oxidase [EC:1.5.3.13] | V+A+ | 1.57 | 2.00 |
| K00306 | SOX | sarcosine oxidase/ L‐pipecolate oxidase [EC:1.5.3.1 1.5.3.7] | V− | −1.04 | −0.87 |
| K01897 | LCFB | long‐chain acyl‐CoA synthetase [EC:6.2.1.3] | V− | −1.33 | −0.34 |
| K11147 | DHRS4 | dehydrogenase/reductase SDR family member 4 [EC:1.1.‐.‐] | V− | −1.81 | −0.67 |
| K00649 | GNPAT | glyceronephosphate O‐acyltransferase [EC:2.3.1.42] | V−A− | −1.48 | −1.44 |
| K03781 | EASC | catalase [EC:1.11.1.6] | A+ | −0.12 | 1.15 |
| K00659 | BAAT | bile acid‐CoA: amino acid | A− | −0.89 | −1.26 |
| Lysosome | |||||
| K12396 | AP3D | AP−3 complex subunit delta | V+ | 1.06 | 0.37 |
| K04646 | CLH | clathrin heavy chain | V+ | 1.04 | 0.4 |
| K01132 | GALNS |
| V− | −1.3 | −0.7 |
| K06129 | PAG15 | lysophospholipase III [EC:3.1.1.5] | A+ | 0.07 | 1.54 |
| K01195 | BGLR | beta‐glucuronidase [EC:3.2.1.31] | A− | −0.48 | −1.22 |
Highly DE cell growth and death genes
| Gene | Symbol | Pathway | Group |
| Apos. |
|---|---|---|---|---|---|
| Apoptosis | |||||
| K04570 | B2CL1 | Bcl‐2‐like 1 (apoptosis regulator Bcl‐X) | V+ | 1.96 | 0.55 |
| K04399 | CASP9 | caspase 9 [EC:3.4.22.62] | V+ | 1.65 | −0.1 |
| K04397 | CASP7 | caspase 7 [EC:3.4.22.60] | V+ | 1.4 | 0.69 |
| K03173 | TRAF2 | TNF receptor‐associated factor 2 [EC:2.3.2.27] | V− | −1.02 | −0.42 |
| K07374 | TBA | tubulin alpha | V− | −1.83 | 0.19 |
| K04451 | P53 | tumor protein p53 | A+ | 0.93 | 1.52 |
| K08731 | BIRC5 | baculoviral IAP repeat‐containing protein 5 | A− | −0.33 | −1.01 |